Respiratory infections have recently become a greater burden on Middle Eastern countries1, with more influenza outbreaks forecasted over the next few years.2 Given that many pathogens have a similar clinical presentation, how can clinicians differentiate between them quickly and cost-effectively?
Boost your laboratory efficiency with the most comprehensive syndromic testing menu for respiratory pathogens! Covering 23 viruses, 14 bacteria, and 1 fungus, Siemens Healthineers’ FTD kits can be easily adapted to your existing molecular diagnostics instrumentation. Multiplex your assays and detect multiple pathogens at the same time, from a single clinical specimen – for a fraction of the price!3
“Thanks to FTlyo FLU/HRSV, laboratories increase their efficiency by simultaneously detecting three significant pathogens during the Middle-East spring season. FTlyo multiplex kits help us reduce our turnaround time and cross-contamination. They provide fast and accurate results for testing of multiple pathogens at the same time.”
Dr. Wafa Elbjeirami
Consultant Virologist, Molecular Diagnostics Laboratory, Department of Laboratory Medicine and Pathology, King Abdullah Medical City, Makkah, Saudi Arabia
Watch the presentation
Syndromic testing for respiratory tract infections: Why epidemiology matters
Professor Dr. med Marcus Panning, Institute of Virology, Medical Center University of Freiburg, Germany
Presentation given at ESCV 2018, Athens, Greece
Sponsored by Siemens Healthineers
Learn more on the clinical utility of multiplex PCR syndromic testing for respiratory infections, and how to address the challenges of testing cost-effectively, while using your existing molecular diagnostic equipment.
References:
Product availability will vary country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.
1 Caini, S. et al. (2018) Influenza and Other Respiratory Viruses, 12(3), pp. 344–352
2 Moghoofei, M. et al. (2017) The Clinical Respiratory Journal, 12, pp. 1787-1801
3 Cost per pathogen, when compared to respective singleplex assays